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Abstract
Spinal Muscular Atrophy (SMA) is an inherited neuromuscular disorder
caused by mutation of the Survival Motor Neuron (SMN1) gene. Embryonic
lethality is rescued by a nearly identical copy of the gene, SMN2, which exists in
variable copy number and produces a small quantity of functional SMN protein.
Because disease severity inversely correlates with SMN2 gene copy number and
with SMN protein level, one therapeutic strategy has been to increase SMN2
expression. Previous investigators have demonstrated that SMN promoter
activity, transcript, and SMN protein are increased in cells treated with histone
deacetylase (HDAC) inhibitors, suggesting a role for histone acetylation in the
regulation of SMN expression.
To further investigate epigenetic regulation of SMN, we used chromatin
immunoprecipitation to characterize the acetylation state of histones associated
with the SMN promoter locus. We show that the SMN promoter has a
reproducible pattern of histone acetylation conserved across species and tissues.
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Following treatment with HDAC inhibitors, we correlated a 2-fold increase in SMN
promoter activity, with an increase in H3 and H4 histone acetylation, particularly
in upstream regions 2-3 kb from the translational initiation site. During
development in mouse tissues, SMN transcript decreased 40-60%, correlating
with a decrease in histone acetylation levels within the region closest to the
transcriptional start site. These data indicate that histone acetylation is a
biologically relevant determinant of SMN gene expression, and that this
epigenetic variable can be manipulated pharmacologically.
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Introduction

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular
disease for which there is currently no treatment. It is the leading inherited cause
of infant mortality with an incidence of 1 in 6-10,000 live births and a carrier
frequency of 1-2% (1-3). Clinically, SMA is characterized by profound muscle
weakness in a symmetrical distribution, with proximal muscles more affected
than distal, and lower extremities more than upper. In addition to weakness,
patients often exhibit hypotonia, hyporeflexia and tongue fasciculations (1). In
contrast to patients with other neurodegenerative diseases such as amyotrophic
lateral sclerosis (ALS), the disease course is generally not progressive. Patients
with SMA show little or no decline in objective muscle strength after an initial
phase of decline (1, 4). Pathologic analysis of spinal cord and muscle from
human autopsies and mouse models of SMA show a pattern of axonal
degeneration with subsequent denervation of muscle fibers, although it is not
clear that particular groups of motor neurons are disproportionately affected (5,
6).
SMA is clinically divided into three forms. SMA type I, or WerndigHoffman disease, is the most severe form and accounts for over 50% of cases.
These patients present within the first six months of life, are never able to sit
unaided, and die by the age of 2 years. In the most severe of these cases,
mothers will feel a cessation of fetal movement before birth and the infants will
die within the first few months of life. Type II patients experience the onset of
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symptoms within the first 18 months of life, are able to sit but not stand unaided,
and can live into early adulthood. Type III patients present later, can have a
normal lifespan, and are able sit and stand unaided at some point in their lives,
although they are usually wheelchair bound. Interestingly, patients will usually
develop normally at first, then plateau, failing to attain developmental milestones
of strength, rather than experiencing a significant loss of strength. The primary
source of mortality in all patients is respiratory failure due to weakness of the
muscles of inspiration (1, 7).
Spinal muscular atrophy is caused by deletion or mutation of the Survival
Motor Neuron (SMN1) gene, located at 5q13 (8). An inverted near duplicate of
the gene, SMN2, is present in variable copy number centromeric to SMN1. Due
to a C to T base change in a splice-enhancing region of SMN2, 70-85% of the
mRNA produced from SMN2 is lacking exon 7 (9). The protein produced from
the truncated SMN2 mRNA is unstable and thought to be rapidly degraded (10).
A small fraction of the mRNA produced from SMN2 (15-30%) is full length and
codes for a fully functional SMN protein, providing enough SMN for cell survival,
and to prevent the early embryonic lethality seen in species lacking SMN2. Not
surprisingly, severity of symptoms in spinal muscular atrophy is inversely
correlated with SMN2 copy number, and with the amount of SMN protein present
in the spinal cord (11).
SMN is a ubiquitously expressed protein with a well-established function in
splicing (12, 13) and a putative role in mRNA transport (14, 15). SMN is present
and necessary for survival in all cells, evoking the question of why motor neurons
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are uniquely sensitive to low levels of SMN. The SMN complex, composed of
SMN and at least 6 gemin proteins, plays an essential role in assembly of small
nuclear ribonucleoproteins (snRNPs). SMN has binding sites for gemin-2
(formerly SMN interacting protein-1 or SIP-1) and for RNA. It is found primarily in
the nucleus in discrete “gems”, for gemini of coiled bodies, and is also found at
the nucleolar membrane and diffusely within the nucleoplasm and cytoplasm
(12). More recently, SMN has been visualized at the leading edge of motor
neuron growth cones (16) and has been shown to associate with the mRNA of βactin, suggesting a role for SMN in the enrichment of particular mRNAs
necessary for developing growth cones (14, 15).
When observed under the microscope, affected motoneurons from mouse
models of SMA and from human autopsies display the typical “ballooning”
phenotype of degenerating neurons (5, 6, 17). Accumulations of neurofilaments
have been described, consistent with the hypothesis that cytoskeletal
disorganization contributes to the pathogenesis of SMA (6). Reduced
synaptophysin staining is also observed in affected motoneurons suggesting a
loss of synaptic contact (5). Muscle biopsies in SMA can vary widely depending
on disease severity. In adults with type III SMA, fibers show typical neuropathic
changes with fibers that are atrophic and band or triangular shaped in cross
section, and grouping of type 1 and 2 fibers indicating reinnervation. In a child
with type I SMA, fibers are smaller in diameter than normal but remain circular,
without the fiber type-grouping pattern seen with reinnervation. These patterns
have been correlated electrophysiologically (5, 6).
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Because of its early onset and lack of significant progression, SMA has
been postulated to be a disease of development. In normal individuals, SMN
protein has been shown to be highly expressed during development, with a
dramatic decrease in the post-natal period and into adulthood (18). In embryonic
chick P19 cells, cellular differentiation to a mature neuronal phenotype is also
associated with a decrease in SMN levels (19). Knockdown of SMN mRNA in a
zebrafish model was found to impair motor axon outgrowth and pathfinding (20).
Taken together, these data suggest that SMN may play a role in neuronal
development, and that SMA may in fact be a developmental disorder. It has
been postulated that in affected individuals, developmental down-regulation of
the gene causes SMN protein levels to fall below some absolute threshold,
resulting in lack of viability in developing motor neurons, and the cessation of
further development in motor strength.
Since the recognition that SMA is caused by a lack of SMN protein,
increasing SMN2 expression has become one of the most promising strategies
for treatment of SMA (21). The finding that histone deacetylase inhibitors can
increase SMN2 expression in vitro, suggested that histone acetylation, an
important epigenetic determinant of gene expression, might play a role in SMN2
expression. Histone deacetylases (HDACs), in conjunction with histone
acetyltransferases (HATs), control the balance of acetylation of histone H3 and
H4 “tails” (22). Increased histone acetylation has been correlated with increased
gene expression, and decreased acetylation with decreased gene expression
(22, 23). This was thought to be due to repel forces between the acetyl groups
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and the negatively charged phosphate backbone of the DNA, creating more
space at the site of transcription binding. More recently, a “histone code” has
been described in which modifications (acetylation, methylation, phosphorylation,
and sumoylation) of particular residues on histone amino terminus tails create a
template for transcription factor binding within a gene’s promoter (24). Inhibitors
of HDACs have been shown to increase global histone acetylation, and to alter
expression in approximately 2% of genes (25). Several groups have shown that
compounds which inhibit histone deacetylases can increase SMN2 expression in
vitro (26-29) and improve survival in vivo (28). Despite their relative
nonspecificity, HDAC inhibitors are now being evaluated in limited clinical trials
for use in SMA (21).
Currently available HDAC inhibitors are known to act on most of the 10
individual HDACs from classes I and II that have been identified to date. Class I
HDACs, including HDACs 1,2,3, and 8, are similar to the yeast RPD3 protein,
and localize primarily to the nucleus. Class II HDACs, including HDACs 4,5,6,7,9
and 10, are similar to the yeast HDA1 protein, and localize to both the nucleus
and the cytoplasm. Class III HDACs are the most structurally distinct. They are
NAD-dependent enzymes similar to the yeast SIR2 proteins, and are not
susceptible to inhibition by Trichostatin A, the prototypical HDAC inhibitor (30).
HDACs are thought to increase SMN expression by activating the SMN
promoter. The human SMN1 and SMN2 promoters are nearly identical in
sequence and activity (9, 19, 31), with a principal transcriptional initiation site
located 163 bp upstream of the translational initiation site. Recently, a second
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transcriptional initiation site used during fetal development and in undifferentiated
P19 cells, has been identified at 242 bp, 79 bp upstream of the primary site (32).
The SMN promoter was originally thought to encompass a 3.4kb region (19), but
recent data suggests that all the elements needed for activation are present
within the first 180bp. Sequences with negative regulatory activity have,
however, been found as far as 4.6 kb from the translational initiation site (33).
Mice have a single Smn gene, analogous to our SMN1, which shares sequence
homology with the human SMN promoters (33, 34). Transcription factor analysis
shows likely binding sites for a number of factors, including Sp1, CREB and YY1
(31). Recently, Sp and Ets cis-elements, working in combination, have been
shown to promote activation in neuronally differentiated P19 cells (32).
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Statement of purpose, specific hypothesis, and specific aims of the
thesis

The purpose of our study was to investigate the role of histone acetylation
in expression of SMN. We hypothesized that histone acetylation would have a
consistent baseline pattern along the promoter, likely with an increase in
acetylation close to the site of transcription initiation, as described at other gene
site (35, 36). We also hypothesized that an increase in histone acetylation within
the promoter would correlate with an increase in SMN promoter activation and
gene expression, and that this effect would be both biologically significant and
vulnerable to pharmacologic manipulation.
Specifically, our first aim was to characterize the baseline histone
acetylation pattern at the SMN promoter using chromatin immunoprecipitation
with primer-probe sets mapped at ∼500 bp intervals along the promoter and first
exon. We mapped promoter histone acetylation in mouse neuronal cells, in
human fibroblast cells from SMA patients, and in mouse brain, spinal cord, liver
and kidney tissues. Although HDAC inhibitors have been previously to increase
SMN promoter activation, their specific mechanism of action remains poorly
understood. We therefore characterized changes in histone acetylation within
the SMN promoter following treatment with different HDAC inhibitors.
Next, we characterized the developmental pattern of SMN transcript and
protein in mice using tissue lysates from brain, spinal cord, liver and kidney
extracted from mice at E15, P1, P7, P15 and adult (3 month) time points. We
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then investigated a correlation between the developmental decrease in SMN
expression and a change in promoter acetylation.
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Materials and Methods:

Cell culture and treatment
NSC-34 cells, a mouse motor neuron-neuroblastoma hybrid cell line, were
maintained in Dulbecco’s Minimal Essential Medium containing 5% heatinactivated fetal bovine serum, 1% Penicillin-Streptomycin-Gentamicin and 1%
Geneticin (Gibco, Carlsbad, CA). These cells are known to express neuronal
properties including generation of action potentials, and acetylcholine synthesis,
storage and release (37, 38). The cells were stably transfected with a 3.4 kb
fragment of the SMN promoter linked to a β-lactamase reporter gene. Cells were
split 1:3 every 2-3 days. We also used a fibroblast line derived from a skin
biopsy from a SMA patient with 2 copies of the SMN2 gene (GM03813, Coriell
Cell Repositories, Camden, NJ, USA). Fibroblasts were maintained in Minimal
Essential Medium containing 15% fetal bovine serum and 1% PenicillinStreptomycin-Gentamicin. For experiments, cells were treated with media alone
or with media containing valproic acid (VPA, Sigma, St. Louis, MO, USA),
valpromide (VPM, Katwijk Chemie BV, The Netherlands), or suberoylanalide
hydroxamic acid (SAHA, Calbiochem, San Diego, CA, USA) at the appropriate
concentration.

Mouse tissue
C57/Black 6 mice (Charles River Labs, Wilmington, MA) were
anesthetized with isoflurane and sacrificed by cervical dislocation (P7, P15, and
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adult) or decapitation (E15 and P1). Brain, spinal cord, kidney and liver tissues
were dissected from the mice at ages E15, P1, P7, P15 and three-four months,
and were flash frozen in liquid nitrogen. Tissue was thawed on ice immediately
before use for protein extraction, RNA extraction, or chromatin
immunoprecipitation.

Promoter activity
SMN2 promoter activity was measured in transfected NSC-34 cells as a
function of β-lactamase cleavage of a fluorogenic substrate, CCF-2AM (PanVera,
Invitrogen, Carlsbad, CA, USA), as previously described (26). Cells were plated
500,000 per well in a 96-well plate in serum-free media with or without valproic
acid or valpromide, and incubated for twenty-four hours. β-lactamase activity
was assayed according to the manufacturer’s protocol. Data is presented as a
ratio of emission at 460 nm, representing cleaved substrate, over emission at
530 nm, representing uncleaved substrate.

Protein extraction and Western blotting
Protein was homogenized in 1 ml of lysis buffer (50 mM Tris-HCl, 0.1%
Nonidet P-40, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA [Sigma])
and kept at 4º C throughout the extraction process. Homogenates were
centrifuged at 4000 rpm for 10 minutes to reduce the foam, sonicated at 35%
power for 5-10 seconds to lyse the cells, then centrifuged again at 14,000 rpm for
30 minutes to separate the protein fraction. Protein concentration was
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determined by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) according
to the manufacturer’s instructions. Protein lysates (10 mg) were denatured in
sample buffer containing β-mercaptoethanol (Sigma) at 95˚C for five minutes,
then run on 12% Tris-Glycine gels with SDS Tris-Glycine running buffer
(Invitrogen) for approximately 1.5 hours at 125 V. Protein was transferred to
nitrocellulose membranes in transfer buffer (Invitrogen) at 25 V for 2 hours.
Nonspecific binding was blocked with 5% (w/v) nonfat dry milk in TTBS.
Membranes were probed with mouse monoclonal anti-SMN primary antibody at
1:5000 (Transduction Laboratories, San Diego, CA, USA) then goat anti-mouseHRP secondary antibody at 1:2000 (Santa Cruz Laboratories, Santa Cruz, CA,
USA), and developed with the Western Lightning chemiluminescence system
according to the manufacturer’s protocol (Perkin-Elmer Life Sciences, Oak
Brook, IL, USA). Blots were stripped and re-probed with anti-β actin at 1:2000
(Sigma), then stripped and blotted a third time with anti-α tubulin at 1:4000
(Sigma). Density of bands was determined using NIH Image software.

RNA extraction and quantification
Tissue was homogenized in 1 ml TRIzol/50-100mg tissue (Invitrogen) and
spun at 12,000 rpm for 10 minutes to separate the low molecular weight nucleic
acid fraction. Cells were washed with PBS and suspended in 1 ml TRIzol. RNA
was extracted as previously described (26) using 0.2 ml chloroform/ 1 ml TRIzol.
After the addition of TRIzol, the samples were vortexed vigorously then
centrifuged at 12,000 g for 10 minutes at 4˚C. The aqueous phase was
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transferred to a fresh tube with 0.5 ml isopropyl alcohol/1 ml TRIzol. Samples
were centrifuged at 12,000 g for 10 minutes at 4˚C and the pellet washed once
with 1 ml of 70% ethanol. Samples were purified with the RNAeasy clean-up kit
according to the manufacturer’s protocol (Qiagen, Valenica, CA, USA). Total
RNA was quantified by absorption at 260 nm, and 50-ng/5 μL was loaded into
each 25-μL real time, reverse transcriptase-PCR reaction. The level of SMN
RNA was quantified by the ΔΔCt method using 18S as an endogenous control on
the ABI Prism 7900 in 96-well plates (Applied Biosystems, Foster City, CA, USA).
SMN primers and probes were 5’ to 3’ as follows: SMN forward:
GAATGCCACAACTCCCTTG, SMN probe: FAM-CAGTGGAAAGTTGGTGACBHQ, SMN reverse: GCAGCCGTCTTCTGACCAA. Each reaction contained
12.5-μl 2X-reaction buffer, 0.9 μl MgSO4, 1.25 μl of 20X ABI primer-probe mix,
3.1 μl Rox reference dye, 1.75 μl dH2O, 0.5 μl SS-RT Taq, and 5 μl of sample.
Cycling parameters were: 30 minutes at 45 C and five minutes at 95 C, then 50
cycles of 15 seconds at 95 C, 1 minute at 60 C.

Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed on cells and tissue
homogenates as previously described (39-41) using 10 ug of antibody to
acetylated histone subunit H3 (ARTKQTAR AcKSTGG AcKAPRKQLC) or
acetylated histone subunit H4 (AGG AcKGG AcKGMG AcKVGA AcKRHS-C)
(Upstate, Lake Placid, NY, USA). In cell experiments, each condition required
three 150 mm plates of confluent NSC-34 cells, or twelve 150 mm plates of
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fibroblasts. Proteins and DNA in each sample were reversibly cross-linked with
1% formaldehyde (Sigma), 10-mL/150mm plate of cells or 10 μL/mg of tissue, for
10 minutes at 37˚C. Formaldehyde was neutralized by incubation with 1:20 2.5
M glycine at 37˚C for ten minutes (0.5mL/10mL/150mm plate).
Samples were washed three times in 2 ml ice-cold PBS and incubated for
10 minutes on ice in ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl
pH 8.1). For in vitro experiments, cell plates were taken to a cold room (4 C),
where each plate was washed three times in 2 ml ice-cold PBS. Two milliliters of
ChIP lysis buffer was then added to each plate and the cells were scraped off the
plate into the buffer. The cells, now suspended in buffer, were transferred to
three 1.5 ml eppendorf tubes for sonication, 500 μl per tube. DNA was sheared
by sonication (8 x 15 sec.) yielding 0.5-1 kb fragments of DNA. Sonication
efficiency was evaluated in each experiment by running the sonicated chromatin
on a 1% agarose gel. The concentration of each sample was determined by
uncrosslinking 5 μl of sample for one hour at 65˚C in uncrosslinking solution (190
μl lysis buffer containing 40 mM NaCl + 5 μl proteinase K = 5 μl sample), then
reading the optical density at 260 nm. Samples were diluted a minimum of 1:10
in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM
NaCl) to the same final concentration. Chromatin was pre-cleared with 100 μl of
salmon sperm agarose A beads per 6 ml chromatin for one hour at 4˚C. After
centrifuging at 800 rpm for one minute and removing the chromatin to a fresh
tube, 50 μL of chromatin was removed to use as an input control and stored at 80˚C. For each immunoprecipitation, 1.9 ml of chromatin was incubated
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overnight at 4˚C with the antibody of choice, or with no antibody (cells) or
nonspecific IgG (tissue) as a control. Chromatin and antibody were then
incubated with 60 μL of salmon sperm agarose A beads for 1 hour and spun
down at 800 rpm for 1 minute. Each sample was washed for 5 minutes each in
low salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-HCl pH 8.1, 150
mM NaCl), high salt (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH 8.1, 500 mM NaCl), lithium chloride (0.25 M LiCl, 1% Nonidet P-40, 1%
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1) and 2 x TE (10 mM TrisHCl, 1 mM EDTA pH 8.0) buffers with 1 min x 800 rpm centrifugation to remove
each wash. Chromatin was eluted using 1% SDS in water (250 μl 1% SDS x 15
minutes at room temperature on rotation). The beads were centrifuged down
(1000 rpm x 1 minute), and the elute was removed to a fresh tube with 1 ml
insulin needles in order to remove all the elute without disturbing the pellet of
beads. Elution was repeated in 250 μl 1.5% SDS, and the elute was again
removed with 1 ml insulin needles and combined with the 1% SDS elute. Input
samples were thawed and brought to equal volume with 225 μl each of 1% and
1.5% SDS solution. Samples and inputs were uncrosslinked in uncrosslinking
solution (20 μl Tris-HCl pH 6.5, 20 μl 5 M NaCl, 10 μl 0.5M EDTA, 5 μl proteinase
K) at 65˚ C overnight. DNA was extracted with an equal volume (500 μl) of
phenol: chloroform: isoamyl alcohol, 1:1:50, in a gel phase-lock tube (Brinkmann
Instruments, Eppendorf, Germany) and separated at 14,000 rpm x 15 minutes at
room temperature. The organic layer was transferred to two fresh tubes, 250 μL
each, with 3 volumes (750 μL) of 100% ice-cold ethanol. After centrifuging at
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14,000 rpm for 30 minutes, pellets were washed once in 150 μL of 70% ethanol,
air-dried for one hour, and resuspended in PCR-grade ddH2O.
Real time PCR with a standard curve was used to quantitate relative
amounts of DNA. A standard curve for the human gene was generated from the
plasmid containing the human SMN2 promoter used to transfect the NSC-34
cells (Vertex Pharmaceuticals, Cambridge, MA, USA). Mouse experiments used
a standard curve generated from dilutions of whole mouse genomic DNA (Santa
Cruz Biotechnology). Two separate sets of primers and standards were
designed for analysis of the human and mouse promoters (Figure 1). Primers
and probes were designed to amplify six regions of the human SMN2 promoter,
labeled here as HuSP1 (for human SMN promoter), HuSP2, HuSP3, and HuSP4
(Biosource, Camarillo, CA, USA) or six regions of the mouse SMN2 promoter
and exon 1, labeled here as MSP0 (for mouse Smn promoter), MSP1, MSP2,
MSP3, MSP4 and MSP5 (see Table 1). Primers for the mouse beta-globin major
gene were 5’ to 3’ as follows: forward: AGGTGAGGTAGGATCAGTTGCTPCR,
probe: ACTATGTCAGAAGCAAATGT, reverse:
GTGCACCATGATGTCTGTTTCTG. PCR reactions contained an Invitrogen
master mix (2.5 μL 10X platinum buffer, 1.75 μL 50 mM MgCl2, 0.5 μL 10mM
dNTP, 1.25 μL of 20X ABI primer-probe mix, 3 μL Rox, 0.125 μL platinum Taq,
11.825 μL dH2O and 5 μL sample), or an ABI master mix (12.5 μL 2X Universal
Master Mix, 1.25 μL of 20X ABI primer-probe mix, 6.25 μL dH2O). PCR cycling
conditions were: 5 minutes ramping at 95 C, then 40 cycles of 15 seconds at 95
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C, 1 minute at 60 C. After subtracting the baseline no antibody control, values
are expressed as a ratio over the input for each experimental condition.
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Results

The SMN gene has a characteristic pattern of histone acetylation
The chromatin immunoprecipitation assay, known as ChIP, is able to
measure protein interactions with specific regions of DNA in the native chromatin
environment. We used ChIP coupled with real time-PCR to measure the level of
acetylated H3 and H4 histones associated with the SMN promoter and gene.
We first examined the histone acetylation pattern of the mouse Smn gene
in NSC-34 cells, a cell line derived from mouse motor neurons crossed with
neuroblastoma cells (Figure 2). This line was chosen for its motor neuron
characteristics, including the ability to generate action potentials, and to
synthesize, store and release acetylcholine (37, 38). For comparison of
acetylation levels, we used the transcription site region of the mouse β-globin
gene. Histone acetylation is well described at this locus as being relatively
hypoacetylated in tissues where the gene is silent, and hyperacetylated in
erythroid precursor cells, where the gene is expressed at high levels (42). We
found that the regions surrounding the Smn transcriptional initiation site,
designated MSP3 and MSP4 in the mouse genome, were associated with the
highest levels of acetylated H3 and H4 histones, in comparison to the regions
∼1.3-3.5 kb upstream, and ∼1kb downstream. The hypoacetylated regions of the
Smn promoter had comparable levels of histone acetylation to the β-globin gene,
which is transcriptionally silent in this cell type. We next examined the transgenic
human SMN2 promoter and gene, stably transfected randomly into the genome
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of the NSC-34 cell line, and found the same pattern of increased acetylation in
the region of the transcription site, designated HuSP3 and HuSP4, and less
acetylation in regions further upstream.
In order to examine the human SMN gene in its native chromatin
environment, we performed ChIP experiments on fibroblast cell lines derived
from skin biopsies of spinal muscular atrophy patients. In particular, we used the
3813 line from a patient with type I SMA, known to have 2 copies of SMN2 and
deletions in the region of exons 7 and 8 in both copies of SMN1. A similar
pattern was seen at the SMN promoter in the fibroblasts, as was observed in the
transgenic SMN2 in the NSC-34 cells. H3 and H4 acetylation were increased at
HuSP3 and HuSP4 compared to the rest of the SMN promoter sequence and to
the β-globin gene transcription locus. Similar preliminary results were obtained
from fibroblast cell lines 9677 and 2906, derived from patients with SMA type I
and II, no SMN1, and with two and four copies of SMN2, respectively (data not
shown).

Histone deacetylase inhibitors activate the SMN promoter
Histone deacetylase (HDAC) inhibitors have been previously shown to
activate the SMN2 promoter in vitro (26, 29), and have been used in limited
clinical trials as a therapy for spinal muscular atrophy (21). However, these
agents change the expression of ∼2% of genes, and it is unknown whether they
are acting directly at the SMN promoter site. We therefore investigated changes
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in H3 and H4 histone acetylation within the SMN promoter region following
HDAC inhibitor treatment in NSC-34 and 3813 fibroblast cell lines.
We first confirmed SMN2 promoter activation by treating NSC-34 cells
with various drugs for 24 hours and measuring promoter activity (Figure 3). The
vector stably transfected into the NSC-34 cells contains the 3.4kb putative SMN
promoter coupled to a β-lactamase gene, such that promoter activation can be
measured as a function of cleavage of a fluorogenic substrate by β-lactamase.
We found that valproic acid (VPA) increased promoter activation in a dosedependent manner, with a maximum effect of 1.8-fold increased activation over
untreated cells observed at 2.5 mM VPA, as previously described (26, 29).
Valpromide (VPM), a structural analog of valproic acid lacking HDAC inhibitory
activity did not increase SMN promoter activation. Suberoyl anilide hydroxamic
acid (SAHA) also increased SMN2 promoter activity in a dose-dependent manner
by a maximum 2-fold at a concentration of 1 µM. Similar results have been
shown for other HDAC inhibitors (26). Valproic acid has also been shown to
increase SMN RNA and SMN protein in SMA patient fibroblast cell lines (26).
In order to test whether activation of the SMN2 promoter by HDAC
inhibitors is correlated with a change in histone acetylation, we treated NSC-34
cells for 24 hours with 0, 0.5 or 1.0 μM SAHA, then used ChIP coupled with real
time PCR to measure H3 and H4 histone acetylation (Figure 4). We found that
SAHA increased histone acetylation specifically within the upstream regions
hypoacetylated at baseline (HuSP1, HuSP2), but not in the downstream regions
hyperacetylated at baseline (HuSP3, HuSP4) (Figure 7). A maximum 2.3 fold
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increase in H3 histone acetylation over mock treated cells was observed at the
HuSP1 site after treatment with 0.5 μM SAHA, with no increase observed at
HuSP4. A maximum 3.3 fold increase in H4 histone acetylation over mock
treated cells was observed at the HuSP1 site with 1.0 μM SAHA treatment. An
apparent 1.4 fold increase in H4 histone acetylation was observed at HuSP4 at
this same concentration. We also treated 3813 fibroblasts with the HDAC
inhibitor valproic acid for four hours (based on earlier time trial experiments).
Although these data are not conclusive, we observe a maximum 4.4 fold increase
in H3 acetylation at HuSP2 with 5 mM VPA treatment, and a maximum 4.5 fold
increase in H4 acetylation at HuSP1 with 5 mM VPA treatment.

Smn gene expression is developmentally down-regulated
Previous investigators have described a decrease in SMN protein levels
with development (18, 43-45), although this effect has never been wellcharacterized at the mRNA level. Using samples of brain, spinal cord, kidney
and liver tissue, we measured Smn protein and RNA from three animals at each
time point: E15, P1, P7, P15, and adult (three-four months).
For use in Western blots, protein isolates were quantified in triplicate in
two separate assays, and band densities were compared to both α-tubulin and βactin (Figure 5A,B). Neither actin nor tubulin was expressed consistently across
tissue types, with actin significantly less expressed in embryonic liver. In our
assay, we observed a 50-85% decrease in Smn protein in every tissue type
between embryonic and adult time periods, consistent with previous descriptions
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of Smn in development. Interestingly, embryonic liver reliably showed a second,
smaller Smn protein species not seen in other tissues and not previously
reported in human fetal liver (8). This species was present with different Smn
antibodies, and was not present as non-specific staining (data not shown).
In order to better quantify the change in Smn expression during
development in different tissues, and to investigate whether this change was due
to transcriptional or post-translational mechanisms, we measured Smn RNA by
reverse transcriptase real time PCR (Figure 5C). Transcript levels were
analyzed by the ΔΔCt method using two different endogenous controls, 18S and
β-2-microglobulin, for comparison. Overall, a ~40-60% decrease in Smn RNA
was observed in every tissue between E15 and adult ages when compared to
18S RNA (presented here), and an ~85-95% decrease was observed when
compared to β-2-microglobulin. Because 18S was found to increase slightly with
development, the effect shown in the graph is slightly less than the true change
measured by Smn alone. β-2-microglobulin, by contrast, increased slightly with
development, overestimating the change in Smn transcript (data not shown). In
liver, the level of Smn RNA was 30-35% of the other tissues at each time point,
consistent with the lower levels of Smn protein seen in the Western blots.
Interestingly, all three spinal cord samples were significantly lower than
the other two tissues at the P1 time point. Although there was more variation
between individual animals at the adult time point, our data suggest that in the
neural tissues (spinal cord and brain) there is a small increase in Smn expression
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after the nadir observed at P15, a change that is not present in the non-neural
tissues (liver and kidney).

Histone acetylation of the SMN promoter during development
In order to investigate whether histone acetylation plays a role in
regulating SMN/Smn expression in vivo, we looked for a change in histone
acetylation associated with the developmental down-regulation of the Smn gene.
We again used chromatin immunoprecipitation coupled to real time PCR to
examine histone H3 and H4 acetylation at six points along the mouse Smn
promoter and intron 1 in neural (brain) and non-neural (liver) tissue from E15 and
adult mice (Figure 6). Spinal cord could not be used because the quantity of
tissue obtained from the embryonic mice was insufficient. For each chromatin
preparation, roughly 0.2 mg of tissue was used, requiring up to 6-8 individuals in
the case of embryonic brain to reach sufficient quantity of material for the assay.
Each point is the average of at least three chromatin preparations from different
animals, run in triplicate on each of three 384-well PCR plates.
Similar to the pattern of histone acetylation observed in NSC-34 and
fibroblast cell lines, we found that in both liver and brain, the regions immediately
upstream of the transcription initiation site, MSP3 and MSP4, were relatively
hyperacetylated compared to regions further upstream in the promoter (MSP0-2),
and further downstream within the transcribed region (MSP5). This pattern was
conserved between brain and liver, and between developmental time points. In
both tissues, we found that H3 and H4 histone acetylation were approximately
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ten times greater in the most acetylated region, MSP4, than in the least
acetylated regions of MSP0, 1, and 2.
When comparing embryonic to adult liver tissue, acetylation of histones
H3 and H4 decreased at the MSP4 site by 34% and 38% respectively,
corresponding to a 66% decrease in Smn transcript. In brain, H3 and H4
acetylation decreased by 21% and 7% respectively, corresponding to a 40%
decrease in SMN transcript. Generally, little or no change was observed at other
sites, except MSP3 and MSP5 where an increase in acetylation was observed,
primarily limited to H4 in liver. For comparison, we also measured histone
acetylation at the transcription initiation site of the mouse β-globin gene. We
found that in embryonic liver, a major site of hematopoesis, acetylation of the βglobin gene is comparable to hyperacetylated regions of the Smn promoter.
Between E15 and adult samples, acetylation of H3 and H4 histones at the βglobin gene decreased by 88% and 76%, respectively, corresponding to a >99%
decrease in transcript levels. In brain, where the β-globin gene is not expressed
at any point in development, acetylation of the β-globin gene is equivalent to
adult liver and to upstream hypoacetylated regions of the Smn promoter.
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Discussion

Spinal muscular atrophy is an inherited motor neuron disease for which
there is currently no treatment. It is caused by mutation or deletion of SMN1,
leading to insufficient quantities of full length SMN protein. One promising
therapeutic strategy has been increasing expression of the SMN2 gene using
histone deacetylase (HDAC) inhibitors. HDAC inhibitors have previously been
shown to activate the SMN2 promoter, and to increase SMN mRNA and protein
levels (26, 29). However, the mechanism of action for the effects observed with
HDAC inhibitors is not understood, and the role of histone acetylation in directly
regulating SMN expression has never been explored. Here, we use chromatin
immunoprecipitation to look at baseline histone acetylation within the SMN/Smn
promoter, and then investigate changes in that baseline associated with gene
expression changes. We show for the first time that histone acetylation within
the SMN/Smn promoter changes in a site-specific manner following HDAC
inhibitor treatment in vitro, and in association with developmental downregulation of the gene in vivo.
First, a characteristic pattern of histone acetylation is established which is
conserved across cell lines, species, and tissue types. Histones associated with
the translational initiation site are hyperacetylated at both H3 and H4 histone
tails, compared to regions >1 kb upstream, or downstream within exon 1. This
pattern is consistently observed in mouse motor neuron cells, both in the mouse
endogenous gene and the human transgene, in human fibroblasts derived from
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SMA patients, and in mouse tissue from brain, spinal cord, liver, and kidney in
both embryonic and adult mice. This pattern of greater histone acetylation
surrounding the initiation site is consistent with other active genes studied, for
example, in the active human interferon-β (35) and mouse β-globin genes (46).
In genome wide studies of yeast and Drosophila, histones in the 5’ transcribed
region of active genes are generally hyperacetylated compared to histones within
the gene or in more distant regulatory sequences (36, 47).
Interestingly, this region immediately surrounding the translation initiation
site, is the region previously identified as the minimal functional promoter region
(19). More recently, Rouget et al. refined the minimal functional promoter
sequence to 15 bp upstream and 117 bp downstream of the transcriptional start
site for the human SMN gene, and 46 bp upstream and 125 bp downstream of
the transcriptional start site for the mouse Smn gene. In their work, inclusion of
upstream sequence in promoter constructs reduces promoter activity, suggesting
that upstream regions may be involved in repressor activity (32). This is
supported by Boda et al. who found regions with repressor activity as far as
4.6kb upstream (33).
The sequence of the core promoter region is conserved between the
mouse and the human genomes, and contains binding sites for numerous
transcription factors, including cAMP-response element binding protein (CREB)
and Sp (32, 48). The CREB family of transcription factors, in particular, is known
to recruit the highly potent histone acetyltransferase, p300/CREB binding protein
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(CBP) (49), suggesting that recruitment of p300/CBP to the SMN promoter could
be responsible for the high acetylation levels observed in this region.
Next, the 1.7 to1.9- fold increase in SMN/Smn promoter activity previously
observed with HDAC inhibitor treatment (valproic acid and SAHA), is found to
correspond with an increase in H3 and H4 histone acetylation within the
SMN/Smn promoter region. According to our data, histone deacetylase inhibitors
have a specific effect on the acetylation of H3 and H4 histones located further
upstream at sites hypoacetylated at baseline, and no measurable effect on
histones associated with the translational initiation site. These data suggest that
HDAC inhibitors do have an effect within the region of the SMN promoter, but not
at the transcription site, raising the question of whether the HDAC-induced SMN
promoter activation is a direct effect, or secondary to upregulation of some other
molecule, such as a transcription factor. Alternatively, it is known that HDACs
not only deacetylate histones but also non-histone proteins that are
transcriptional regulators (30). Thus, HDAC inhibitor treatment could result in
acetylation and activation of a DNA binding factor that recruits HATs and leads to
acetylation of the SMN2 gene in upstream regions.
In order to examine the biological significance of histone acetylation in
regulation of SMN/Smn expression, experiments were shifted to an in vivo
system, mouse tissue from different developmental time points. Although SMN
protein has long been known to be developmentally down-regulated (18), we
present the first rigorous quantitation of this effect at the mRNA level. A 40-60%
decrease in SMN RNA is seen in all tissues between E15 and adult (three

31
month) mice. Interestingly, both the SMN protein and RNA are lower in liver
tissue, 30-35% of other tissues, at every developmental time point. The
significance of this finding is not known. One limitation of our study is the use of
whole tissue lysates. It has been show by in situ hybridization that the
distribution of SMN in the spinal cord changes with development from being more
diffuse to being specifically concentrated in motor neurons (50), an effect which
is not appreciated in our method. Of note, we found that SMN levels in the spinal
cord dropped significantly more than other tissues at the P1 time point (∼20%),
suggesting that down-regulation of SMN may take place earlier in spinal cord
than in other tissues, and may therefore be subject to different regulatory
mechanisms. Recently, this finding was corroborated in experiments using
sucrose centrifugation followed by western blot, in which the authors show that
the decrease in SMN RNA corresponds to the process of myelination in the
spinal cord, which occurs earlier than in the brain (51).
Finally, we correlated this developmental change in expression with a
change in histone acetylation within the Smn promoter. At the MSP4 site, the
region closest to the transcriptional and translational initiation sites, we observed
a decrease in acetylated H3 and H4 levels in liver tissue, and a decrease in H3
acetylation in brain tissue. This was associated with a 40-60% decrease in Smn
mRNA, as measured by real time RT-PCR. Although the observed decrease in
acetylation is modest, studies in other genes have noted similarly small changes
in acetylation associated with large changes in gene expression. The mouse βglobin gene is perhaps the best studied, in which gene induction produced only a
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two-fold increase in H3 acetylation in association with a 150-fold increase in
expression. Within neighboring regions in the Smn promoter and gene, MSP5
and MSP3, small increases in H3 and H4 acetylation were observed. However,
we believe the decrease at MSP4 is the most relevant as this is the most
transcriptionally active region of the gene. Furthermore, in more recent
experiments, this developmental, regionally specific decrease in acetylation has
been associated with a large increase in HDAC2 and a smaller increase in
HDAC1 within the same region (52).
Although chromatin immunoprecipitation is a powerful technique, its limit
of detection does not extend below 500 bp. Thus the alternate transcription
recently described by Rouget et al. as a site used preferentially during
development could not be distinguished in our work, as it is only 79 bp away from
the adult transcription initiation site (32). It may be that histone acetylation
changes locally within regions smaller than our 500 bp limit of detection.
There has been some controversy in the literature about the use of HDAC
inhibitors as a treatment for spinal muscular atrophy, in particular because of
their lack of specificity, requirements for high doses, and as yet poorly
understood site of action. As mentioned previously, HDAC inhibitors affect the
expression of approximately 2% genes. They also seem to act on most of the
known class I and II HDACs, including those HDACs that act on non-histone
proteins and are located predominantly outside the nucleus (30). HDAC
inhibitors have also been explored for their ability to change the expression of
numerous other genes, including tumor suppressor and oncogenes (reviewed in
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(53), so there is a theoretical risk of activating repressed oncogenes and
increasing the incidence of cancer. Valproic acid is used as an anti-epileptic
medication because of its effect on sodium channels, at a maximum dose of 60
mg/kg/day resulting in serum levels of 50 -100 μg/ml. Even at this dose, which is
lower than the dose required for HDAC inhibition, valproic acid is a known
teratogen and can cause numerous side effects, including mental status
changes. It has been postulated that HDAC inhibition increases SMN expression
by increasing histone acetylation at the SMN promoter, and although the data
presented here support this idea, this has not been proven. Given the need for
high doses, and the poorly understood, nonspecific nature of our current arsenal
of HDAC inhibitors, long-term treatment with high doses of these drugs is likely to
cause significant immediate and long term side effects, and we cannot predict
what these will be.
To address some of these questions, experiments are underway to test
the safety and feasibility of HDAC inhibitor treatment in a mouse model of spinal
muscular atrophy. Further ChIP experiments are also underway using antibodies
against individual HDACs, particularly those in class I, which are concentrated in
the nucleus, in order to determine which particular HDACs may be acting at the
SMN promoter locus. ChIP can also be used to determine other proteins present
at the SMN promoter, for example bound transcription factors or histone
acetyltransferases (HATs). Also important will be to determine the relative
activity of particular inhibitors against individual HDACs, and whether more
specific inhibitors can be developed to target the HDACs active in controlling
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SMN. Together these experiments may allow more specific targeting of the
histone acetylation machinery at the SMN gene locus.
The histone acetylation system described here is only one of the many
epigenetic determinants that may be relevant to the expression of SMN.
Methylation, phosphorylation and sumoylation are well-described histone
modifications known to affect gene expression individually, and to interact with
histone acetylation in controlling gene expression (24, 54). In addition to
affecting immediate transcription factor binding and chromatin accessibility,
histone acetylation is also known to influence long term expression controls such
as DNA methylation. Methylated DNA and the methylation-specific transcription
repressor, MeCP2 have been shown to recruit histone deacetylases (55).
Conversely, treatment with the HDAC inhibitor Trichostatin A, has been reported
to induce loss of methylation at specific genes (56).

Further, a number of

heavily methylated genes studied in vitro have been reported to be unresponsive
to the HDAC inhibitor Trichostatin A without pretreatment with a demethylating
agent (reviewed in (57). These data suggest that treatment with a demethylating
agent plus an HDAC inhibitor may increase the expression of SMN beyond what
each agent can do individually. The effect may even be synergistic, and could
allow the use of lower doses of HDAC inhibitors in the treatment of spinal
muscular atrophy. Further experiments investigating the contributions of other
epigenetic determinants, particularly DNA methylation, may therefore be
warranted.
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In conclusion, we have shown that SMN has a reproducible pattern of
histone acetylation that is modified by HDAC inhibitor treatment and during the
course of development. Together, these data strongly suggest that histone
acetylation plays an important role in SMN/Smn regulation and that this
epigenetic determinant can be manipulated pharmacologically. However, this
work represents a proof of concept, and significant work will be required before
we can hope to exploit this knowledge to have an impact on the course of the
disease. In particular, future experiments should concentrate on investigating
how to more specifically target the histone acetylation machinery at the SMN
locus, and how other epigenetic systems might be exploited to further increase
SMN expression.
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